CITIC Guoan Information Industry (000839.SZ) predicts a net profit of 75-97.5 million yuan for the 2024 fiscal year, turning a loss into a profit compared to the previous year.
CITIC Guoan (000839.SZ) releases the performance forecast for 2024, expecting the full-year attributable to shareholders of the listed company...
CITIC Guoan Information Industry (000839.SZ) has released its performance forecast for the year 2024, expecting a net profit attributable to shareholders of the listed company of 75 to 97.5 million yuan, turning losses into profits year-on-year.
The main reasons for the performance change during the reporting period are as follows: 1. Beijing Honglianjiuwu Information Industry Co., Ltd., a company under CITIC Guoan, has steadily improved its profitability by optimizing its business structure and enhancing service quality, resulting in growth in sales revenue and net profit year-on-year. 2. In order to resolve debt risks and improve efficiency, the company has conducted debt restructuring with relevant parties. The related payment obligations have been fulfilled, resulting in significant debt restructuring gains. This item is classified as non-recurring gains and losses. 3. The net income from fair value changes has decreased compared to the same period last year. This item is also classified as non-recurring gains and losses.
Related Articles

HK Stock Market Move | VENUS MEDTECH-B (02500) up more than 14%, the confirmatory clinical study of CARDIOVALVE TTVR has completed all clinical enrolment.

HK Stock Market Move | ABBISSCO-B(02256)up over 7% during trading, showcasing Phase III clinical trial data for Pimetinib at the 2025 ESMO conference.

HK Stock Market Move | GT GOLD (08299) rises by more than 5% and the company has submitted an application for transfer to the main board. Main board listing is expected to boost valuation and liquidity.
HK Stock Market Move | VENUS MEDTECH-B (02500) up more than 14%, the confirmatory clinical study of CARDIOVALVE TTVR has completed all clinical enrolment.

HK Stock Market Move | ABBISSCO-B(02256)up over 7% during trading, showcasing Phase III clinical trial data for Pimetinib at the 2025 ESMO conference.

HK Stock Market Move | GT GOLD (08299) rises by more than 5% and the company has submitted an application for transfer to the main board. Main board listing is expected to boost valuation and liquidity.

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025


